

## References

### I-9010

1. Hemlibra prescribing information. Gentech Inc. December 2021.
2. Srivastave A, Santagostino E, Dougall A, et al. World Federation of Hemophilia Guidelines for the Management of Hemophilia. 3rd August 2020.
3. National Hemophilia Foundation Bleeding Disorders A-Z Overview Inhibitors Treatment for Inhibitors. <https://www.hemophilia.org/bleeding-disorders-a-z/overview/inhibitors/treatment-for-inhibitors>.
4. Institute for Clinical and Economic Review. Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value. April 2018.
5. National Hemophilia Foundation. Bleeding Disorders A-Z/ Types/ Hemophilia A. Accessed at <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a>
6. CDC Centers for Disease Control and Prevention. Inhibitors and Hemophilia. Accessed at <https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html>
7. National Hemophilia Foundation. One Size Does Not Fit All: Individualized Therapy. Dr Steven Pipe. September 2016. Accessed at <https://www.hemophilia.org/educational-programs/education/online-education/one-size-does-not-fit-all-individualized-therapy>
8. National Hemophilia Foundation. Bleeding Disorders A-Z/ Overview/ Inhibitors/ Immune Tolerance. Accessed at <https://www.hemophilia.org/bleeding-disorders-a-z/overview/inhibitors/immune-tolerance>
9. Medical and Scientific Advisory Council (MASAC) MASAC Document 258 – Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra<sup>®</sup>) for Hemophilia A with and without Inhibitors. March 2020.
10. Institute for Clinical and Economic Review. Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value. November 2020.
11. Clinicaltrials.gov. NCT04023019. Treatment of Hemophilia A Patients With FVIII Inhibitors (MOTIVATE). Accessed at: <https://clinicaltrials.gov/ct2/show/NCT04023019?term=NCT04023019&draw=2&rank=1>
12. Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia Volume 25, Issue 4. April 2019.
13. James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances 12 January 2021. Volume 5, Number 1. 280-300.